Latest Articles
- Lipoprotein ‘little a’: More than a little target in the management of cardiovascular risk?
Lipoprotein(a) was once believed to play no contributory role in the development of cardiovascular disease. That storyline has since flipped.
- Rethinking recovery in heart failure: Beyond improvement in left ventricular ejection fraction
The authors discuss 3 unresolved questions about de-escalating and escalating guideline-directed medical therapy in patients with improved ejection fraction.
- Teprotumumab for thyroid eye disease: A reality check
Initial enthusiasm for teprotumumab as therapy for thyroid eye disease has been tempered by longitudinal data suggesting that it often does not alter the natural disease course.
- Managing obesity in older adults
The goals of treating obesity in older adults are to ease its complications and improve functional status and quality of life, with or without weight loss.
- Failure to thrive in hospitalized older adults: More than a ‘social admission’
Failure to thrive documented as an admitting diagnosis presents an opportunity to identify, articulate, and begin to ameliorate the true underlying causes of the patient’s health deficits.
- Benign migratory glossitis
A 26-year-old woman presented with well-defined erythematous patches on her tongue that had developed over the previous 6 months.
- Nearly a century of using glucocorticoids in patients with active infection
Why would we consider dampening the immune response with glucocorticoids when a patient has an active infection?
- MDA5 dermatomyositis: Unveiling a potentially life-threatening disease
Timely diagnosis and initiation of aggressive immunosuppressive therapy are key to improving the 40% overall mortality rate in patients with MDA5 dermatomyositis.